KR20220057598A - Bcma에 결합하는 이량체성 항원 수용체 (dar) - Google Patents

Bcma에 결합하는 이량체성 항원 수용체 (dar) Download PDF

Info

Publication number
KR20220057598A
KR20220057598A KR1020227011203A KR20227011203A KR20220057598A KR 20220057598 A KR20220057598 A KR 20220057598A KR 1020227011203 A KR1020227011203 A KR 1020227011203A KR 20227011203 A KR20227011203 A KR 20227011203A KR 20220057598 A KR20220057598 A KR 20220057598A
Authority
KR
South Korea
Prior art keywords
region
seq
sequence
amino acid
dar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227011203A
Other languages
English (en)
Korean (ko)
Inventor
헨리 홍준 지
원중 궈
옌량 장
베이 베이 딩
군나르 에프. 카우프만
Original Assignee
소렌토 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소렌토 쎄라퓨틱스, 인코포레이티드 filed Critical 소렌토 쎄라퓨틱스, 인코포레이티드
Publication of KR20220057598A publication Critical patent/KR20220057598A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227011203A 2019-09-05 2020-09-04 Bcma에 결합하는 이량체성 항원 수용체 (dar) Ceased KR20220057598A (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US62/896,190 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US62/896,990 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US62/910,341 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US62/943,069 2019-12-03
US202063030145P 2020-05-26 2020-05-26
US63/030,145 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (1)

Publication Number Publication Date
KR20220057598A true KR20220057598A (ko) 2022-05-09

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011203A Ceased KR20220057598A (ko) 2019-09-05 2020-09-04 Bcma에 결합하는 이량체성 항원 수용체 (dar)

Country Status (10)

Country Link
US (1) US20220251168A1 (https=)
EP (1) EP4025227A4 (https=)
JP (1) JP2022546577A (https=)
KR (1) KR20220057598A (https=)
CN (1) CN114650829A (https=)
AU (1) AU2020341712A1 (https=)
CA (1) CA3149867A1 (https=)
IL (1) IL291076A (https=)
MX (1) MX2022002723A (https=)
WO (1) WO2021046445A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
WO2022226364A2 (en) * 2021-04-23 2022-10-27 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dars) that bind gd2
KR20240051280A (ko) * 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
CN116655805B (zh) * 2023-05-31 2024-03-08 四川大学华西医院 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
PT3294764T (pt) 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
US12195529B2 (en) * 2017-06-21 2025-01-14 Gsbio, Llc Heterodimeric bispecific antibodies
AU2018358067A1 (en) * 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
SG11202008568WA (en) * 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma

Also Published As

Publication number Publication date
EP4025227A4 (en) 2023-11-01
MX2022002723A (es) 2022-03-22
CA3149867A1 (en) 2021-03-11
JP2022546577A (ja) 2022-11-04
WO2021046445A1 (en) 2021-03-11
CN114650829A (zh) 2022-06-21
EP4025227A1 (en) 2022-07-13
US20220251168A1 (en) 2022-08-11
AU2020341712A1 (en) 2022-03-31
IL291076A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
US20240294639A1 (en) Antigen-binding proteins targeting cd56 and methods of producing thereof
US12180294B2 (en) Dimeric antigen receptors
WO2020135559A1 (en) Cd30-binding moieties, chimeric antigen receptors, and uses thereof
US20220251168A1 (en) Dimeric Antigen Receptors (DAR) that Bind BCMA
JP2020506700A (ja) 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
US20230192848A1 (en) Engineered cell compositions and methods of use thereof
US20260091062A1 (en) Recombinant Fc domain - IL2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
CN112041432A (zh) Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
US20230061838A1 (en) Dimeric Antigen Receptors (DAR) That Bind CD20
US20230167191A1 (en) Memory Dimeric Antigen Receptors (mDARs)
US20240197881A1 (en) Dimeric Antigen Receptors (DARs) that Bind GD2
CN117545493A (zh) 与gd2结合的二聚体抗原受体（dar）
WO2025233304A1 (en) Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601